Last reviewed · How we verify
NCT04766190: DISCO
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
NA trial testing Group 2: The DISCO App in Financial Toxicity in 260 participants. Currently enrolling.
31 August 2027
Quick facts
| Lead sponsor | Lauren Hamel |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 260 |
| Start date | 10 February 2021 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Group 2: The DISCO App
- Group 1: Usual Care
- Group 3: The DISCO App + Booster
Conditions studied
- Financial Toxicity — all drugs for Financial Toxicity →
- Cancer — all drugs for Cancer →
- Question Prompt List — all drugs for Question Prompt List →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Lauren Hamel
Who can join
18 and older, any sex, with Financial Toxicity or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The DISCO App is designed to improve, during the interaction, patient active participation and patient-initiated oncologist treatment cost discussions, and, in the short term, patient's treatment cost knowledge, self-efficacy for managing both cost and physician interactions, referrals, perceived financial toxicity (i.e., distress and material hardship); in turn, these will affect longer-term outcomes of financial toxicity and adherence.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population.
Hamel LM, Dougherty DW, Kim S, Heath EI, et al · · 2021 · cited 11× · PMID 34535162 · DOI 10.1186/s13063-021-05593-y -
DISCO App: Study Protocol for a Randomized Controlled Trial to Test the Effectiveness of a Patient Intervention to Reduce the Financial Burden of Cancer In a Diverse Patient Population
Hamel LM, Dougherty DW, Kim S, Heath EI, et al · · 2021 · DOI 10.21203/rs.3.rs-389676/v1
Verify or expand the search:
- PubMed search for NCT04766190
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Financial Toxicity
Currently open trials in the same condition.
- NCT07215611 — Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas · recruiting
- NCT07281287 — Evaluating the Implementation and Impact of Standard-of-care Delivered Oncology Financial Navigation · NA · recruiting
- NCT06461780 — Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766190 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lauren Hamel
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766190.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing